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Background: A major reason of the poor control of asthma is that patients fail to adhere to
their treatment. The aim of the study was to identify factors affecting changes in asthma
treatment adherence in an international cohort.
Methods: A follow-up study was carried out by means of a structured clinical interview in
971 subjects with asthma from 12 countries who participated in both the European
Community Respiratory Health Survey: ECRHS-I (1990–94) and ECRHS-II (1998–2002).
Subjects were considered adherent if they reported they normally took all the prescribed
drugs. A logistic model was used to study the adjusted effect of the determinants.
Results: The net change in adherence to anti-asthmatic treatment per 10 years of follow-
up was 2% (95% CI: 9.5, 5.5), 7.5% (2.6, 17.6), 15.0% (6.6, 23.5) and 19.8% (4.1, 35.5),Elsevier Ltd. All rights reserved.
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Figure 1 Flow chart of the selectio
those participating to ECRHS-II.
A.G. Corsico et al.1364respectively, in Nordic, Mediterranean, Continental and extra-European areas. Among the
428 non-adherent subjects in ECRHS-I, having regular consultations with health care
professionals was the strongest predictor of increased adherence (OR 3.32; 95% CI:
1.08–10.17). Among the 543 adherent subjects in ECRHS-I, using inhaled corticosteroids
significantly predicted a persistence of adherence (OR 2.04; 95% CI: 1.11–3.75). No effect
of gender, age, duration of the disease, smoking habit and educational level was observed.
Conclusions: Our findings highlight the key role of doctors and nurses in educating and
regularly reviewing the patients and support the efforts for an improvement of clinical
communication.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Medication regimens for asthma care are particularly vulner-
able to adherence problems because of their duration, the use
of multiple medications mostly delivered as inhalation, and the
periods of symptom remission. Identifying the specific reasons
for non-adherence is essential in order to determine the best
way to intervene and to increase the control of asthma.1–7
In the frame of the European Community Respiratory
Health Survey I (ECRHS-I, 1990–1994) we documented that
self-reported adherence was poor worldwide.8 The follow-
up study (ECRHS-II) carried out in 1998–2002 provided us
with the opportunity to study factors affecting changes in
asthma treatment adherence in population cohorts from a
large number of different countries.Methods
The methods for the ECRHS-I and ECRHS-II have been
published in detail elsewhere9,10 and further information is
available at the study’s website [www.ecrhs.org]. The flown of the study population from4of subjects over time from ECRHS-I and II is shown in Fig. 1.
The study population were 971 subjects (398 men, 573
women; mean age at the first survey 34.077.2 years) who
had ever suffered from asthma confirmed by a doctor in
ECRHS-I or II, had been prescribed asthma treatment and
had answered questions on adherence in both ECRHS-I and II.
The patients’ adherence to anti-asthmatic treatment
during the stable condition was evaluated by the following
question: ‘‘If you have been prescribed medicine for your
breathing, do you normally take all the medicine?’’.8
The following adherence-related variables were consid-
ered: Geographic macroareas (Mediterranean, Continental,
Nordic, Extra-European); smoking habit; educational level;
duration of asthma; having taken inhaled corticosteroids in
the previous 12 months or not; patients’ beliefs about their
therapy; having regular appointments for asthma with a
doctor or a nurse; having written instructions from a doctor;
having a personal peak expiratory flow (PEF) meter; having
had spirometry during the previous 12 months.
Ethics approval was obtained for each center from the
appropriate ethics committee, and written consent was
obtained from each participant.18,000 subjects participating to the clinical stage of ECRHS-I to
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Table 1 Mutually adjusted OR (95% CI) for the association between adherence-related variables and increased adherence or
persistent adherence, respectively, among the 428 non-adherent subjects and among the 543 adherent subjects in ECRHS I.
Increased adherence Persistent adherence
Sex
Man 1.0 1.0
Woman 0.80 (0.39, 1.66) 1.29 (0.72, 2.32)
Age 1.00 (0.95, 1.05) 1.03 (0.99, 1.07)
Macroarea
Mediterranean 1.0 1.0
Continental 0.96 (0.22, 4.11) 0.74 (0.26, 2.13)
Nordic 0.26 (0.06, 1.14) 0.22 (0.08, 0.59)
Extra-European 0.24 (0.03, 2.00) 1.82 (0.28, 11.84)
Duration of asthma 1.00 (0.98, 1.04) 1.00 (0.97, 1.03)
Smoking habits in ECRHS I
Non-smokers 1.0 1.0
Past smokers 0.63 (0.23, 1.74) 1.07 (0.52, 2.18)
Current smokers 0.42 (0.18, 1.01) 0.71 (0.37, 1.38)
Full time education
Till 16-year old or less 1.0 1.0
More than 16-year old 1.01 (0.13, 1.92) 1.06 (0.52, 3.08)
Type of drug in ECRHS I
No ICS 1.0 1.0
ICS 1.15 (0.43, 3.06) 2.04 (1.11, 3.75)
Written instructions
No 1.0 1.0
Yes 1.33 (0.96, 4.38) 0.73 (0.35, 1.52)
PEF meter
No 1.0 1.0
Yes 1.78 (0.76, 4.17) 1.66 (0.86, 3.23)
Spirometry in the last 12 months
No 1.0 1.0
Yes 1.60 (0.39, 6.52) 1.78 (0.55, 5.75)
Regular appointments for asthma
No 1.0 1.0
Yes 3.32 (1.08, 10.17) 1.23 (0.55, 2.75)
Thinking it is bad to take medicines all the time to help breathing
No 1.0 1.0
Yes 0.13 (0.06, 0.31) 0.82 (0.46, 1.46)
Thinking they should take as much medicine needed to cure problems
No 1.0 1.0
Yes 2.05 (0.96, 4.38) 1.09 (0.60, 1.99)
ECRHS ¼ European Community Respiratory Health Survey; OR ¼ odds ratio; CI ¼ confidence interval; ICS ¼ inhaled corticosteroids;
PEF ¼ peak expiratory flow.
Mediterranean area ¼ Spain, France (except for Paris), Italy; Continental area ¼ Belgium, Germany, The Netherlands, UK,
Switzerland, Paris; Nordic area ¼ Iceland, Norway, Sweden, Estonia; extra-European area ¼ Portland, USA, Melbourne, Australia.
International changes in adherence 1365Statistics
Absolute net change in adherence status per year of follow-
up was estimated using population averaged generalized
estimating equations, with participants identified as the
clustering factor and duration of follow-up as an indepen-dent variable. Results are expressed as net change per 10
years of follow-up. Estimates from each area were examined
for heterogeneity using the test statistic Q.11 To study the
adjusted effect of the determinants of any change
in adherence during the follow-up and to allow for potential
sources of heterogeneity in the design of the study, a
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A.G. Corsico et al.1366two-level logistic random intercept model was used12 (Stata
software, release 8.0; Stata Corp, College Station, TX, USA).Results
The mean length of follow-up was 8.171.4 years. There
were no significant differences in asthma treatment
adherence in ECRHS-I between those who participated in
the follow-up and those who did not.
The adherence to anti-asthmatic treatment in ECRHS-II
was 53.4%, 56.1%, 67.6%, 76.4% and the net change per 10
years of follow-up was 2% (95% CI: 9.5%, 5.5), 19.8% (4.1,
35.5), 7.5% (2.6, 17.6) and 15.0% (6.6, 23.5), respectively,
in Nordic, extra-European, Mediterranean and Continental
areas, with significant between-areas heterogeneity
ðp ¼ 0:009Þ.
Among the 428 non-adherent subjects in ECRHS-I, the only
predictors of increased adherence among the variables
considered were having regular appointments for asthma or
not thinking that it is bad to take medicine all the time
(Table 1).
Among the 543 adherent subjects in ECRHS-I, subjects using
inhaled corticosteroids were significantly more likely to be
persistently compliant; in contrast, subjects living in Nordic
countries were less likely to be still compliant (Table 1).
Gender, age at baseline, duration of the disease, smoking
habit, educational level, having written instruction from a
doctor, having a personal PEF meter and having had
spirometry during the previous 12 months were not significant
determinants for the improvement or the persistence of
adherence to antiasthmatic treatment (Table 1).Discussion
The main findings of our study are that during the follow-up
of this international cohort of young and middle-aged
adults: (1) adherence to asthma treatment remained low
worldwide although it significantly increased in Continental
and extra-European areas and (2) the major predictors of
increased or persistent adherence are having regular follow-
up consultations with health care professionals, and having
positive beliefs about the medications.
Despite the significant improvement observed in Australia
and USA, the countries with the lowest adherence and the
highest morbidity from asthma in the early 1990s,8
adherence with asthma treatment remains far from optimal.
Our results substantiate that frequent contact with patients
is a key factor for adherence to asthma treatment,
highlighting the importance of a frequent reviewed and
reinforced partnership between patients and health care
professionals.13–16 The significant negative association we
found between concerns about adverse effects of medica-
tions and adherence to therapy shows once again that real
fears exist, have a major influence on attitude and behavior
in asthma management and should receive particular
attention during asthma consultation. On the other hand,
to our knowledge, this is the first study to report a positive
association between using inhaled corticosteroids and
adherence to treatment showing that fears about corticos-
teroids side-effects may be overcome, likely by thepatients’ perceptions of the benefits of taking therapy and
by appropriate information.
The main strength of this investigation is the large sample
from many different countries, its prospective design and
the time period over which it has been conducted. In fact, to
our knowledge, this is the first prospective study on the
change in adherence to anti-asthmatic treatment in an
international cohort since international guidelines have
been introduced.17
Our study has some limitations. First, changes in social,
economic and geographical barriers that have taken place in
eastern part of Europe during the 1990s may have affected
our analysis,18,19 but only to a minor extent. In fact, when
excluding Germany and Estonia from the analysis the main
results did not change. Second, self-reports of adherence
are not the most accurate modality to estimate patient
adherence. Certainly, the most reliable methods that are
available in the clinical setting could not be used in large
epidemiological surveys.20 In our study the questions were
not asked by the doctor who prescribed the treatment and
self-reported overestimation due to the patients’ desire to
‘‘please’’ should be limited. At variance, adherence may be
overestimated during a controlled trial with several visit to
the clinic than during long-term ‘‘real life’’.
In conclusion, further improvement in asthma manage-
ment through an improvement in the quality of clinical
communication is required because non-adherence still
remains a major health care problem across countries.Acknowledgements
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